Optimal bevacizumab treatment strategy in advanced ovarian cancer
Episode notes
The addition of bevacizumab to chemotherapy has been shown to improve progression-free survival (PFS) in patients with ovarian cancer, with the greatest benefit observed in those with high-risk disease, and the combination of bevacizumab and olaparib has been approved as a first-line maintenance treatment for patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer.
The results of the study include the finding that bevacizumab is associated with improved PFS in both platinum-resistant and platinum-sensitive recurrent OC. The study also found that bevacizumab combined with olaparib maintenance therapy may provide substantial benefits for patients with newly diagnosed advanced OC and homologous recombination deficiency-positive tumors.
The results of the study show that bevacizumab can be used across multiple lines of therapy in individual patients to control disease effectively, and that combining bevacizumab with olaparib as maintenance therapy may be beneficial in both higher- and lower-risk patients in the first-line setting.
The limitations of the study include the fact that the optimal bevacizumab treatment strategy for AOC is still debated. The study also notes that there are no established predictive biomarkers to aid in selecting patients for bevacizumab treatment.
The limitations of the studies include that they were not designed to compare the efficacy of bevacizumab in the first-line versus recurrent setting. Another limitation is that the studies did not investigate the optimal sequencing of bevacizumab treatment.
Monk BJ, Lorusso D, Fujiwara K, Sehouli J. Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. Cancer Treat Rev. 2025 Jun;137:102945. doi: 10.1016/j.ctrv.2025.102945. Epub 2025 Apr 20. PMID: 40349571.